Volitionrx Ltd: Lagoda Investment Management Makes Purchase

February 15, 2018 - By Hazel Jackson

 Volitionrx Ltd: Lagoda Investment Management Makes Purchase

Investors sentiment increased to 7 in Q3 2017. Its up 3.00, from 4 in 2017Q2. It is positive, as 0 investors sold VolitionRx Limited shares while 1 reduced holdings. 2 funds opened positions while 5 raised stakes. 9.30 million shares or 4.95% less from 9.78 million shares in 2017Q2 were reported.

Bessemer Gru holds 0% or 10,000 shares in its portfolio. Northern Trust reported 0% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX). Moreover, Creative Planning has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX). Bancorp Of New York Mellon holds 30,376 shares or 0% of its portfolio. Moreover, Tower (Trc) has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX) for 6,832 shares. Garrison Bradford & reported 15,500 shares or 0.03% of all its holdings. Blackrock invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Knoll Capital Management Lp reported 1.06% stake. Southpoint Capital Advsrs Limited Partnership holds 265,482 shares or 0.03% of its portfolio. Geode Cap Mngmt Limited Liability Co accumulated 100,890 shares or 0% of the stock. Citigroup has invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Pennsylvania-based Vanguard Gru has invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). California-based Leisure Cap Mgmt has invested 0.17% in VolitionRx Limited (NYSEAMERICAN:VNRX). Morgan Stanley invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Royal Comml Bank Of Canada holds 0% or 14,007 shares in its portfolio.

The New Lagoda Investment Management Holding in Volitionrx Ltd

Lagoda Investment Management reported SC 13G/A form with the SEC for Volitionrx Ltd. Access it here: 000090571818000202. As reported by Lagoda Investment Management, the filler owns 13.2% or 3,516,963 shares of the -company.

Volitionrx Ltd stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Lagoda Investment Management’s positive view for Volitionrx Ltd. For a institutional investor managing $725.00 million in assets and having 11+ experts this is interesting position.

Volitionrx Ltd Institutional Sentiment

Filings show 8 investors own Volitionrx Ltd. The ownership in Q3 2015 is very low, at Infinity of the outstanding shares. This is increased by 89026. 939555 were owned by these investors. 4 funds opened new Volitionrx Ltd stakes, 1 increased positions. There were 2 that closed positions and 1 reduced them.

Goldman Sachs Group Inc is an investor bullish on Volitionrx Ltd, owning 45874 shares as of Q3 2015 for less than 0.01% of its portfolio. Israel Englander Millennium Management Llc owns 26858 shares or less than 0.01% of its portfolio. NY Garrison Bradford & Associates Inc have 0.08% of its portfolio for 15500 shares. Further, Kcg Holdings Inc reported stake worth less than 0.01% of its portfolio. The NY Southpoint Capital Advisors Lp owns 800000 shares. Volitionrx Ltd is 0.16% of its portfolio.

Business Profile

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company’s Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company’s NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.

SEC Form 13G.

Analysts await VolitionRx Limited (NYSEAMERICAN:VNRX) to report earnings on March, 9. They expect $-0.16 earnings per share, down 33.33 % or $0.04 from last year’s $-0.12 per share. After $-0.15 actual earnings per share reported by VolitionRx Limited for the previous quarter, Wall Street now forecasts 6.67 % negative EPS growth.

The stock decreased 1.51% or $0.0453 during the last trading session, reaching $2.9547. About 6,972 shares traded. VolitionRx Limited (NYSEAMERICAN:VNRX) has declined 0.29% since February 15, 2017 and is downtrending. It has underperformed by 16.99% the S&P500.

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers. The company has market cap of $78.36 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It currently has negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

More notable recent VolitionRx Limited (NYSEAMERICAN:VNRX) news were published by: Prnewswire.com which released: “VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business …” on November 09, 2017, also Prnewswire.com with their article: “VolitionRx Limited Announces the Formation of Volition America, Inc.” published on March 20, 2017, Quotes.Wsj.com published: “News VolitionRX Ltd.VNRX” on May 24, 2014. More interesting news about VolitionRx Limited (NYSEAMERICAN:VNRX) were released by: Marketwatch.com and their article: “VolitionRX Ltd.” published on September 26, 2016 as well as Prnewswire.com‘s news article titled: “VolitionRx Limited Announces Acquisition of New Belgian Facility and …” with publication date: October 26, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.